PSMA PET/CT-Based Decision Can Predict Treatment Progression

By Robert Dillard - June 21, 2022

Most men with biochemically recurrent prostate cancer require no addition or change in their treatment plans made based on prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) during three years of follow-up, according to a study published online May 31 in Cancers.

Sean Ong, MD, from the E.J. Whitten Prostate Cancer Research Centre at Epworth HealthCare in Richmond, Australia, and colleagues examined the clinical impact of PSMA PET/CT by analyzing its predictive value for treatment progression after a follow-up of three years in a prospective cohort study of 100 men. Patients received a PSMA PET/CT for disease restaging, which a multidisciplinary team used to make a treatment decision. Treatment progression, defined as the addition or change of any treatment modalities, was the primary end point.

The researchers found that 75% of patients had no treatment progression, and 25% had treatment progression. In men with negative PSMA PET/CT, five and 28 of 33 (15.1% and 84.8%, respectively) had treatment progression and no treatment progression, respectively.

“In men with negative PSMA PET-CT results, a higher rate of men had no treatment progression,” the authors write. “This should provoke further prospective studies regarding the timing of PSMA PET-CT and initiation of treatment for men with recurrent prostate cancer.”

The study was funded by AstraZeneca.